Clinical Trial Update: A Study of Therapeutic Iobenguane (131-I) and Vorinostat for Recurrent or Progressive High-Risk Neuroblastoma Subjects [Phase 2]

View source ↗

Summary

Phase 2 trial investigating iobenguane (131-I) with vorinostat for recurrent or progressive high-risk neuroblastoma; current status not disclosed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroblastoma

Drugs mentioned

• Vorinostat (vorinostat)
• iobenguane (131-I) (iobenguane)

Snippet

Sponsor: Jubilant DraxImage Inc. | Conditions: Neuroblastoma, Neuroectodermal Tumors | Phase 2 | Status: UNKNOWN